ClinicalTrials.gg
CompletedNCT02918318Updated Apr 29, 2025Results posted

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

A Phase 2 interventional study of Placebo and Intranasal esketamine (28 mg) in Depression, sponsored by Janssen Pharmaceutical K.K.. Completed at 46 sites in Japan. Open to participants aged 20 Years to 64 Years. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Janssen Pharmaceutical K.K. (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
202
Allocation
Randomized
Ages
20 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing esketamine in Depression — 11 open to participants now, 12 under way, 1 of them phase 3. Esketamine · Depression.

Enrollment
12th of 28
202 · median 156
Started
2016
the only one that year
Phase 2
3 of 28
none open now
Registered
2nd of 28
by date
Lead sponsor
1 of 28
Janssen Pharmaceutical K.K.

Among the 28 studies testing esketamine in Depression, this one is the 12th largest by enrollment, is the only one that started in 2016, is one of 3 in phase 2, and was the 2nd registered.

Depression

8,595 studies on the registry are indexed under Depression; 1,732 are open to participants now.

Browse Depression studies →

Open to participants now

11 of the 28 studies testing esketamine in Depression are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About esketamine

Esketamine: first FDA approval 2019 (SPRAVATO), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,094 Depression studies recruiting now, 472 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 314 take healthy volunteers.

This study: 20 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing esketamine in Depression, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of fixed dosed intranasal esketamine compared to intranasal placebo, as an add-on to an oral antidepressant in Japanese participants with treatment-resistant depression (TRD), in improving depressive symptoms.

03

Conditions studied

  • Depression

Browse trials for

04

Who can participate

Ages eligible
20 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At the start of the screening phase, participant must meet the (DSM-5) diagnostic criteria for single-episode major depressive disorder (MDD) or recurrent major depressive disorder (MDD), without psychotic features, based upon clinical assessment and confirmed by the Mini International Neuropsychiatric Interview (MINI). In the case of single-episode MDD, the participant must be diagnosed with persistent depressive disorder, which meets criteria of major depressive episode for a continuous duration of greater than or equal to (>=)2 years, and the same physician from the site must be examining the participant for >=2 years continuously as a primary care physician of the participant
  • The participant's current major depressive episode, depression symptom severity (MADRS total score greater than or equal to [>=] 28 required), and antidepressant treatment response in the current depressive episode, must be confirmed using the SAFER interview
  • Participant must be medically stable on the basis of clinical laboratory tests, physical examination, medical history, vital signs (including blood pressure), pulse oximetry, and 12-lead (ECG) performed in the screening phase
  • A woman of must have a negative highly sensitive serum Beta (β) human chorionic gonadotropin [β-hCG] test at the start of the screening phase and a negative urine pregnancy test must be obtained before the first dose of study drug on Day 1 of the double-blind induction phase prior to randomization
  • use by men or women should be consistent with local regulations regarding the use of contraceptive methods for participant participating in clinical studies

Exclusion criteria

Exclusion Criteria:

  • Participant has received vagal nerve stimulation or has received deep brain stimulation in the current episode of depression
  • Participant previously received esketamine or ketamine as treatment for their MDD
  • Participant has homicidal ideation/intent, per the investigator's clinical judgment, or has suicidal ideation with some intent to act within 6 months prior to the start of the screening phase
  • Participant has a history of moderate or severe substance or alcohol use disorder according to criteria, except nicotine or caffeine, within 6 months before the start of the screening phase
  • Participant has a current or past history of seizure disorder (uncomplicated childhood febrile seizures with no sequelae are not exclusionary)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
202 participants (actual)

Study arms

  • Experimental
    Placebo

    Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.

    Drug: Placebo

  • Experimental
    Esketamine 28 milligram (mg)

    Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.

    Drug: Intranasal esketamine (28 mg)

  • Experimental
    Esketamine 56 mg

    Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.

    Drug: Intranasal esketamine (56 mg)

  • Experimental
    Esketamine 84 mg

    Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.

    Drug: Intranasal esketamine (84 mg)

Interventions

  • DrugPlacebo

    Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.

  • Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.

  • Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.

  • Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.

06

What researchers measure

Primary outcomes

  1. Double-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

    Time frame: Baseline (Day 1) up to Day 28 (DB phase) induction

Secondary outcomes

  1. DB Induction Phase: Percentage of Participants With Response Based on MADRS Total Score

    A participant is defined as responder (yes=1 and no=0) at a given time point if the percent improvement from baseline in MADRS is greater than or equal to (\>=) 50 percent (%). MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Days 2, 8, 15, 22 and 28 (DB induction phase)

  2. DB Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score

    A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Days 2, 8, 15, 22 and 28 (DB induction phase)

  3. DB Induction Phase: Percentage of Participants Showing Onset of Clinical Response

    A participant was defined as having a clinical response if there was at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that was maintained to Day 28 in DB induction phase. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, provided the score is at least 25% improvement. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Day 2 up to Day 28 (DB induction phase)

  4. DB Induction Phase: Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score up to Day 28

    CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.

    Time frame: Baseline (Day 1) up to Day 28 (DB induction pahse)

  5. DB Induction Phase: Change From Baseline in Generalized Anxiety Disorder 7-Item Scale (GAD-7) up to Day 28

    GAD-7 was a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).

    Time frame: Baseline (Day 1) up to Day 28 (DB induction phase)

  6. DB Induction Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28

    SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.

    Time frame: Baseline (Day 1) to Day 28 (DB induction phase)

  7. Posttreatment Phase: Time to Relapse in Participants With Remission (MADRS Total Score <=12)

    Time to relapse in participants with remission at the end of the double-blind phase was defined as the time between induction phase and the first documentation of a relapse event during the posttreatment phase. Relapse was defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse; 2) Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.

    Time frame: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)

  8. Posttreatment Phase: Time to Relapse in Participants With Response (>=50% Reduction From Baseline in MADRS Total Score) But Who Are Not in Remission

    Time to relapse in participants with response (\>=50% reduction from baseline in MADRS total score) but who are not in remission was reported. Relapse is defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse. 2)Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.

    Time frame: From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)

  9. Posttreatment Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Weeks 2, 4, 6, 8, 12, 16, 20 and 24

    SDS is a participant-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. FAS (responders): All randomized participants who received at least 1 dose of intranasal study medication during DB induction phase and who were responders at the end of DB induction phase and entered posttreatment phase

    Time frame: Baseline (DB induction phase), Weeks 2, 4, 6, 8, 12, 16, 20 and 24 (posttreatment phase)

  10. OL Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score

    A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Days 8, 15, 22 and 28 (OL induction phase)

  11. OL Induction Phase: Change From Baseline (Prior to the First Dose of OL Induction Phase) in MADRS Total Score up to Endpoint OL Induction Phase (Last Post Baseline Assessment Value During the OL Induction Phase [OL: up to Day 28])

    MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

    Time frame: Baseline (Prior to first Dose of OL induction phase on Day 1) up to endpoint of OL induction phase (last post baseline assessment value during OL induction phase [OL: up to Day 28])

  12. OL Induction Phase: Percentage of Participants With Severity of Psychopathology on the CGI-S Scale

    CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time.

    Time frame: Baseline (Prior to first dose of OL induction phase on Day 1), endpoint of OL induction phase (last post baseline assessment value during the OL induction phase [OL: up to Day 28])

07

Results

Posted Oct 19, 2020
Limitations and caveats
Esk has transient dissociative effects that are difficult to blind, these specific events could have biased clinical staff who observed treatment sessions. To ensure an unbiased efficacy evaluation, remote, blinded MADRS raters were used.

Participant flow

Double-blind Induction Phase: 4 Weeks
Participant flow — Double-blind Induction Phase: 4 Weeks
MilestoneEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboEsketamine: Flexible Dose
Started414041800
Responders131117270
Completed393339720
Not completed27280
Withdrew: Adverse event14230
Withdrew: Lack of efficacy00020
Withdrew: Lost to follow-up00010
Withdrew: Withdrawal by subject11000
Withdrew: Non-compliance00010
Withdrew: Other02010
Double-blind Follow-up Phase: 4 Weeks
Participant flow — Double-blind Follow-up Phase: 4 Weeks
MilestoneEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboEsketamine: Flexible Dose
Started272824530
Completed262823500
Not completed10130
Withdrew: Withdrawal by subject00020
Withdrew: Adverse event10110
Posttreatment Phase: Up to 24 Weeks
Participant flow — Posttreatment Phase: Up to 24 Weeks
MilestoneEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboEsketamine: Flexible Dose
Started131117270
Completed12816250
Not completed13120
Withdrew: Withdrawal by subject10010
Withdrew: Other03110
Open Label Treatment Phase: 4 Weeks
Participant flow — Open Label Treatment Phase: 4 Weeks
MilestoneEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboEsketamine: Flexible Dose
Started000048
Completed000047
Not completed00001
Withdrew: Adverse event00001
Open Label Follow-up Phase: 4 Weeks
Participant flow — Open Label Follow-up Phase: 4 Weeks
MilestoneEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboEsketamine: Flexible Dose
Started000048
Completed000047
Not completed00001
Withdrew: Adverse event00001

Outcome measures

PrimaryDouble-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition. Negative change in score indicates improvement.

Time frame:
Baseline (Day 1) up to Day 28 (DB phase) induction
Reported as:
Mean · Units on a scale
Double-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28
Units on a scaleEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
Double-Blind (DB) Induction Phase: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score up to Day 28-15.2 ± 13.07-14.5 ± 10.53-15.1 ± 12.21-15.3 ± 11.68
Statistical analysis
  • Esketamine 28 Milligrams (mg) vs Placebo · Dunnett adjustment · p = 0.475 (1-sided) · Difference of least squares means: -1.0 · 90% CI -5.77 to 3.70
  • Esketamine 56 mg vs Placebo · Dunnett adjustment · p = 0.504 (1-sided) · Difference of least squares means: 0.6 · 90% CI -4.32 to 5.47
  • Esketamine 84 mg vs Placebo · Dunnett adjustment · p = 0.482 (1-sided) · Difference of least squares means: -0.9 · 90% CI -5.66 to 3.83
SecondaryDB Induction Phase: Percentage of Participants With Response Based on MADRS Total Score

A participant is defined as responder (yes=1 and no=0) at a given time point if the percent improvement from baseline in MADRS is greater than or equal to (\>=) 50 percent (%). MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Days 2, 8, 15, 22 and 28 (DB induction phase)
Reported as:
Number · Percentage of participants
DB Induction Phase: Percentage of Participants With Response Based on MADRS Total Score
Percentage of participantsEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
Day 222.013.210.09.0
Day 82.42.69.83.8
Day 1517.58.315.018.2
Day 2223.113.920.529.7
Day 2833.335.343.637.5
SecondaryDB Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score

A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Days 2, 8, 15, 22 and 28 (DB induction phase)
Reported as:
Number · Percentage of participants
DB Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score
Percentage of participantsEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
Day 29.807.53.8
Day 82.404.91.3
Day 157.52.810.03.9
Day 2210.35.67.714.9
Day 2823.111.823.120.8
SecondaryDB Induction Phase: Percentage of Participants Showing Onset of Clinical Response

A participant was defined as having a clinical response if there was at least 50% improvement from baseline in the MADRS total score with onset by Day 2 that was maintained to Day 28 in DB induction phase. Participants were allowed one excursion (non-response) on Days 8, 15 or 22, provided the score is at least 25% improvement. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Day 2 up to Day 28 (DB induction phase)
Reported as:
Number · Percentage of participants
DB Induction Phase: Percentage of Participants Showing Onset of Clinical Response
Percentage of participantsEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
Onset of clinical response: Yes2.42.67.36.3
Onset of clinical response: No97.697.492.793.7
SecondaryDB Induction Phase: Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score up to Day 28

CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. Values of 0 (not assessed) were excluded from analysis. CGI-S permits global evaluation of participant's condition at given time.

Time frame:
Baseline (Day 1) up to Day 28 (DB induction pahse)
Reported as:
Median · Units on a scale
DB Induction Phase: Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score up to Day 28
Units on a scaleEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
DB Induction Phase: Change From Baseline in Clinical Global Impression - Severity (CGI-S) Total Score up to Day 28-1.0 (-5 to 1)-1.0 (-3 to 0)-1.0 (-5 to 0)-1.0 (-4 to 1)
SecondaryDB Induction Phase: Change From Baseline in Generalized Anxiety Disorder 7-Item Scale (GAD-7) up to Day 28

GAD-7 was a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21).

Time frame:
Baseline (Day 1) up to Day 28 (DB induction phase)
Reported as:
Mean · Units on a scale
DB Induction Phase: Change From Baseline in Generalized Anxiety Disorder 7-Item Scale (GAD-7) up to Day 28
Units on a scaleEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
DB Induction Phase: Change From Baseline in Generalized Anxiety Disorder 7-Item Scale (GAD-7) up to Day 28-8.2 ± 4.94-7.8 ± 5.05-8.1 ± 5.67-7.7 ± 5.05
SecondaryDB Induction Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28

SDS is a participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability. First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0(no impairment)-10 (most severe impairment). Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement. It also has one item on days lost from school or work and one item on days when under productive.

Time frame:
Baseline (Day 1) to Day 28 (DB induction phase)
Reported as:
Mean · Units on a scale
DB Induction Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28
Units on a scaleEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
DB Induction Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score up to Day 28-8.6 ± 8.68-7.9 ± 7.94-9.5 ± 8.93-7.0 ± 7.39
SecondaryPosttreatment Phase: Time to Relapse in Participants With Remission (MADRS Total Score <=12)

Time to relapse in participants with remission at the end of the double-blind phase was defined as the time between induction phase and the first documentation of a relapse event during the posttreatment phase. Relapse was defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse; 2) Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.

Time frame:
From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
Reported as:
Median · Days
Posttreatment Phase: Time to Relapse in Participants With Remission (MADRS Total Score <=12)
DaysEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
Posttreatment Phase: Time to Relapse in Participants With Remission (MADRS Total Score <=12)34.0 (26.0 to NA)52.0 (20.0 to 80.0)37.0 (19.0 to 71.0)30.0 (22.0 to 50.0)
SecondaryPosttreatment Phase: Time to Relapse in Participants With Response (>=50% Reduction From Baseline in MADRS Total Score) But Who Are Not in Remission

Time to relapse in participants with response (\>=50% reduction from baseline in MADRS total score) but who are not in remission was reported. Relapse is defined as any of the following: 1) MADRS total score \>= 22 for 2 consecutive assessments. The date of the second MADRS assessment was used for the date of relapse. 2)Hospitalization for worsening depression or any other clinically relevant event determined per clinical judgment to be suggestive of relapse of depressive illness like suicide attempt, completed suicide, or hospitalization for suicide prevention. If hospitalized for any of these events, start date of hospitalization was used as relapse date. If participant was not hospitalized, event date was used. 3) If both relapse criteria were met, earlier date was defined as date of relapse. Remission was defined as MADRS total score \<=12.

Time frame:
From EndPoint (last post baseline assessment value during the DB induction phase [up to Day 28]) up to 24 weeks (posttreatment phase)
Reported as:
Median · Days
Posttreatment Phase: Time to Relapse in Participants With Response (>=50% Reduction From Baseline in MADRS Total Score) But Who Are Not in Remission
DaysEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
Posttreatment Phase: Time to Relapse in Participants With Response (>=50% Reduction From Baseline in MADRS Total Score) But Who Are Not in Remission32.0 (13.0 to 44.0)26.0 (9.0 to 121.0)79.5 (16.0 to 108.0)91.0 (22.0 to NA)
SecondaryPosttreatment Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Weeks 2, 4, 6, 8, 12, 16, 20 and 24

SDS is a participant-reported outcome measure and is a 5-item questionnaire which has been widely used and accepted for assessment of functional impairment and associated disability. The first three items assess disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items are summed to create a total score of 0-30, where a higher score indicates greater impairment. It also has one item on days lost from school or work and one item on days when under productive. FAS (responders): All randomized participants who received at least 1 dose of intranasal study medication during DB induction phase and who were responders at the end of DB induction phase and entered posttreatment phase

Time frame:
Baseline (DB induction phase), Weeks 2, 4, 6, 8, 12, 16, 20 and 24 (posttreatment phase)
Reported as:
Mean · Units on a scale
Posttreatment Phase: Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Weeks 2, 4, 6, 8, 12, 16, 20 and 24
Units on a scaleEsketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlacebo
Week 2-14.6 ± 7.82-8.1 ± 6.15-13.1 ± 7.65-11.2 ± 6.83
Week 4-12.9 ± 5.69-8.3 ± 2.75-13.6 ± 7.34-9.8 ± 5.84
Week 6-17.7 ± 8.50-11.0 ± 3.61-14.6 ± 5.53-12.0 ± 4.39
Week 8-12.0 ± 14.42-13.3 ± 1.53-15.3 ± 7.15-11.4 ± 6.02
Week 12-20.5 ± 3.54-13.0 ± 7.21-18.3 ± 7.76-14.8 ± 4.88
Week 16-21.5 ± 6.36-17.5 ± 0.71-12.5 ± 21.92-15.8 ± 1.89
Week 20-22.0 ± 7.07-18.0-28.0-14.0 ± 3.65
Week 24-21.5 ± 4.95-16.0-28.0-14.8 ± 3.59
SecondaryOL Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score

A participant was considered in remission at a given time point if the MADRS total score \<=12. MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Days 8, 15, 22 and 28 (OL induction phase)
Reported as:
Number · Percentage of participants
OL Induction Phase: Percentage of Participants With Remission Based on MADRS Total Score
Percentage of participantsEsketamine: Flexible Dose
Day 814.6
Day 1523.4
Day 2231.9
Day 2842.6
SecondaryOL Induction Phase: Change From Baseline (Prior to the First Dose of OL Induction Phase) in MADRS Total Score up to Endpoint OL Induction Phase (Last Post Baseline Assessment Value During the OL Induction Phase [OL: up to Day 28])

MADRS is clinician-rated scale designed to measure depression severity, and to detect changes due to antidepressant treatment. Scale consists of 10 items (apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, and suicidal thoughts), each of which is scored from 0 (item is not present or is normal) to 6 (severe or continuous presence of symptoms), summed for a total possible score of 0 to 60. Higher scores represent more severe condition.

Time frame:
Baseline (Prior to first Dose of OL induction phase on Day 1) up to endpoint of OL induction phase (last post baseline assessment value during OL induction phase [OL: up to Day 28])
Reported as:
Mean · Units on a scale
OL Induction Phase: Change From Baseline (Prior to the First Dose of OL Induction Phase) in MADRS Total Score up to Endpoint OL Induction Phase (Last Post Baseline Assessment Value During the OL Induction Phase [OL: up to Day 28])
Units on a scaleEsketamine: Flexible Dose
Baseline16.1 ± 9.47
Change from baseline-14.5 ± 11.06
SecondaryOL Induction Phase: Percentage of Participants With Severity of Psychopathology on the CGI-S Scale

CGI-S provides measure of severity of participant's illness including participant's history, psychosocial circumstances, symptoms, behavior and impact of symptoms on ability to function. CGI-S evaluates severity of psychopathology on scale of 0 to 7. Considering total clinical experience, participant is assessed on severity of mental illness according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among most extremely ill patients. CGI-S permits global evaluation of participant's condition at given time.

Time frame:
Baseline (Prior to first dose of OL induction phase on Day 1), endpoint of OL induction phase (last post baseline assessment value during the OL induction phase [OL: up to Day 28])
Reported as:
Number · Percentage of participants
OL Induction Phase: Percentage of Participants With Severity of Psychopathology on the CGI-S Scale
Percentage of participantsEsketamine: Flexible Dose
Normal, not at all ill:Baseline0
Normal, not at all ill:Endpoint14.6
Borderline mentally ill:Baseline0
Borderline mentally ill:Endpoint16.7
Mildly ill:Baseline4.2
Mildly ill:Endpoint43.8
Moderately ill:Baseline75.0
Moderately ill:Endpoint20.8
Markedly ill:Baseline14.6
Markedly ill:Endpoint4.2
Severely ill:Baseline4.2
Severely ill:Endpoint0
Among the most extremely ill patients:Baseline2.1
Among the most extremely ill patients:Endpoint0

Adverse events

Collected over Up to 42 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind (DB): Esketamine 28 mg0/41 (0%)1/41 (2.4%)33/41 (80.5%)
DB: Esketamine 56 mg0/41 (0%)0/41 (0%)39/41 (95.1%)
DB: Esketamine 84 mg0/40 (0%)1/40 (2.5%)39/40 (97.5%)
DB: Placebo0/80 (0%)1/80 (1.3%)34/80 (42.5%)
DB Follow Up (FU): Esketamine 28 mg0/27 (0%)0/27 (0%)3/27 (11.1%)
DB FU: Esketamine 56 mg0/29 (0%)0/29 (0%)3/29 (10.3%)
DB FU: Esketamine 84 mg0/23 (0%)1/23 (4.3%)3/23 (13%)
DB FU: Placebo0/53 (0%)2/53 (3.8%)7/53 (13.2%)
Post-Treatment (PT) Phase: Esketamine 28 mg0/13 (0%)0/13 (0%)6/13 (46.2%)
PT Phase: Esketamine 56 mg0/11 (0%)0/11 (0%)4/11 (36.4%)
PT Phase: Esketamine 84 mg0/17 (0%)0/17 (0%)6/17 (35.3%)
PT Phase: Placebo0/27 (0%)0/27 (0%)7/27 (25.9%)
Open-Label (OL): Flexible Esketamine0/48 (0%)1/48 (2.1%)47/48 (97.9%)
OL FU: Flexible Esketamine0/48 (0%)2/48 (4.2%)3/48 (6.3%)
Most frequent serious events
Most frequent serious events
EventDouble Blind (DB): Esketamine 28 mgDB: Esketamine 56 mgDB: Esketamine 84 mgDB: PlaceboDB Follow Up (FU): Esketamine 28 mgDB FU: Esketamine 56 mgDB FU: Esketamine 84 mgDB FU: PlaceboPost-Treatment (PT) Phase: Esketamine 28 mgPT Phase: Esketamine 56 mgPT Phase: Esketamine 84 mgPT Phase: PlaceboOpen-Label (OL): Flexible EsketamineOL FU: Flexible Esketamine
Muscular WeaknessMusculoskeletal and connective tissue disorders0/410/410/400/800/270/291/230/530/130/110/170/270/480/48
Cerebral DisorderNervous system disorders0/410/410/400/800/270/291/230/530/130/110/170/270/480/48
Suicidal IdeationPsychiatric disorders0/410/411/401/800/270/290/230/530/130/110/170/270/480/48
FractureInjury, poisoning and procedural complications1/410/410/400/800/270/290/230/530/130/110/170/270/480/48
Atrioventricular Block Second DegreeCardiac disorders0/410/410/400/800/270/290/230/530/130/110/170/270/481/48
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/410/410/400/800/270/290/230/530/130/110/170/270/481/48
Suicide AttemptPsychiatric disorders0/410/410/400/800/270/290/231/530/130/110/170/271/480/48
Ankle FractureInjury, poisoning and procedural complications0/410/410/400/800/270/290/231/530/130/110/170/270/480/48
Most frequent other events
Showing 10 of 46
Most frequent other events
EventDouble Blind (DB): Esketamine 28 mgDB: Esketamine 56 mgDB: Esketamine 84 mgDB: PlaceboDB Follow Up (FU): Esketamine 28 mgDB FU: Esketamine 56 mgDB FU: Esketamine 84 mgDB FU: PlaceboPost-Treatment (PT) Phase: Esketamine 28 mgPT Phase: Esketamine 56 mgPT Phase: Esketamine 84 mgPT Phase: PlaceboOpen-Label (OL): Flexible EsketamineOL FU: Flexible Esketamine
DissociationPsychiatric disorders14/4110/4122/407/800/270/290/230/530/130/110/170/2731/480/48
Blood Pressure IncreasedInvestigations12/4119/4119/408/800/270/290/230/530/130/110/170/2724/480/48
DizzinessNervous system disorders11/4118/4115/405/801/271/290/231/531/130/110/170/2721/480/48
SomnolenceNervous system disorders10/4113/4111/4014/800/270/290/231/531/130/110/170/2711/480/48
NauseaGastrointestinal disorders7/417/418/407/800/270/290/232/530/130/110/170/2712/480/48
VertigoEar and labyrinth disorders4/417/418/401/800/270/290/230/530/130/110/170/276/480/48
HypoaesthesiaNervous system disorders7/418/415/404/800/270/290/230/530/130/110/170/276/481/48
NasopharyngitisInfections and infestations1/410/411/403/802/271/291/233/532/132/112/173/272/482/48
AstheniaGeneral disorders2/417/413/400/800/270/290/230/530/130/111/170/273/480/48
HeadacheNervous system disorders6/415/414/403/800/270/291/230/530/130/111/172/278/480/48

Baseline characteristics

Full analysis set (FAS) included all randomized participants who received at least 1 dose of intranasal study agent.

Age, Continuous
Age, Continuous(years)Esketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboTotal
Mean45.9 ± 9.9742.5 ± 8.3641.9 ± 10.2643.3 ± 11.443.4 ± 10.35
Sex: Female, Male
Sex: Female, Male(Participants)Esketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboTotal
Female2316183996
Male18242341106
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Esketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboTotal
Hispanic or Latino00000
Not Hispanic or Latino41404180202
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Esketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboTotal
American Indian or Alaska Native00000
Asian41404180202
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White00000
More than one race00000
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(Participants)Esketamine 28 Milligrams (mg)Esketamine 56 mgEsketamine 84 mgPlaceboTotal
JAPAN41404180202
08

Study locations

46 sites
  • Akita, Japan
  • Fukui-shi, Japan
  • Fukuoka-Shi, Japan
  • Fukuoka, Japan
  • Gunma, Japan
  • Hachinohe-shi, Japan
  • Hachioji-shi, Japan
  • Hirakata, Japan
  • Hiratsuka-shi, Japan
  • Hokkaido, Japan
  • Ibaraki, Japan
  • Ichikawa, Japan
  • Kanzaki-gun, Japan
  • Karatsu, Japan
  • Kashihara, Japan
  • Kawasaki, Japan
  • Kita-Azumi, Japan
  • Kita-Ku, Japan
  • Kitakyushu, Japan
  • Kobe, Japan
  • Kochi, Japan
  • Kodaira, Japan
  • Komoro-shi, Japan
  • Kumamoto, Japan
  • Kure, Japan
  • Kurume-shi, Japan
  • Kyoto, Japan
  • Maizuru, Japan
  • Morioka, Japan
  • Nagakute, Japan
  • Nagasaki, Japan
  • Okayama-shi, Japan
  • Okayama, Japan
  • Okinawa, Japan
  • Osaka, Japan
  • Sapporo-shi, Japan
  • Setagaya-ku, Japan
  • Shibuya-ku, Japan
  • Shinjuku-ku, Japan
  • Shinjuku, Japan
  • Takatsuki-shi, Japan
  • Toyoake, Japan
  • Ube, Japan
  • Yokohama-shi, Japan
  • Yokohama, Japan
  • Yonago, Japan
09

References and documents

Publications

  • Ohnishi T, Wakamatsu A, Kobayashi H. Different symptomatic improvement pattern revealed by factor analysis between placebo response and response to Esketamine in treatment resistant depression. Psychiatry Clin Neurosci. 2022 Aug;76(8):377-383. doi: 10.1111/pcn.13379. Epub 2022 Jun 9. PubMed 35596932 ↗
  • Takahashi N, Yamada A, Shiraishi A, Shimizu H, Goto R, Tominaga Y. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study. BMC Psychiatry. 2021 Oct 25;21(1):526. doi: 10.1186/s12888-021-03538-y. PubMed 34696742 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Aug 2019, 32 months.

Results were first posted in Oct 2020, 1 year 2 months after primary completion.

Of 53 industry-sponsored phase 2 interventional studies under Depression, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 29. This study's 32 months is above that.

Counting every sponsor, half of 196 studies reached it within 31 months; a quarter within 18 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Sep 28, 2016
StartActual
Dec 12, 2016
Primary completionActual
Aug 19, 2019
CompletionActual
Dec 13, 2019
Results first posted
Oct 19, 2020
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02918318
Responsible party
Sponsor
First posted
Sep 28, 2016
Start date
Dec 12, 2016
Primary completion
Aug 19, 2019
Completion
Dec 13, 2019
Results posted
Oct 19, 2020
Last update
Apr 29, 2025

Study contacts

Janssen Pharmaceutical K.K., Japan Clinical Trial
study director · Janssen Pharmaceutical K.K.

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Esketamine

Start the discussion